SOUTH SAN FRANCISCO, Calif. , July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2021 financial results on Thursday,
A New Platform to Simplify Deep Profiling of the Human Immune System SOUTH SAN FRANCISCO, Calif. , May 25, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the
FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy SOUTH SAN FRANCISCO, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
SOUTH SAN FRANCISCO, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in several upcoming
SOUTH SAN FRANCISCO, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,
Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive
SOUTH SAN FRANCISCO, Calif. , April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday,
Collaboration Agreement to Market AZOVA COVID-19 Test Collection Kit Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase , Sample Collection, and Secure Delivery of Test Results SOUTH SAN FRANCISCO, Calif.
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 million Collaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH
